Abstract
Sympathetic neural factors are involved in energy balance as well as in blood pressure control. This represents the background for the hypothesis that an adrenergic overdrive may be implicated in the development and/or progression of the metabolic syndrome. Indirect and direct markers of sympathetic drive have confirmed this hypothesis, by showing the occurrence of an adrenergic activation both at the cardiac and peripheral vascular level. It is likely that this sympathetic dysfunction is triggered by reflex mechanisms (arterial baroreceptor impairment), metabolic factors (insulin resistance), and humoral agents (angiotensin II, leptin). The adrenergic overdrive exerts a number of adverse effects on the cardiovascular system, by favoring the genesis of cardiac hypertrophy, vascular hypertrophy, arterial remodeling and endothelial dysfunction and thereby aggravating the already elevated cardiovascular risk profile of the patient. This carries obvious clinical and therapeutic implications, including the suggestion that sympathetic inhibition should be included among the goals of both pharmacological and non-pharmacological interventions employed in the treatment of the metabolic syndrome.
Similar content being viewed by others
Article PDF
References
Reaven GM, Lithell H, Landsberg L : Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374–381.
Morrison SF : Central pathways controlling brown adipose tissue thermogenesis. News Physiol Sci 2004; 19: 67–74.
Grassi G : Role of the sympathetic nervous system in human hypertension. J Hypertens 1998; 16: 1979–1987.
Grassi G, Mancia G : Neurogenic hypertension: is the enigma of its origin near the solution? Hypertension 2004; 43: 154–155.
Amerena J, Julius S : The role of the autonomic nervous system in hypertension. Hypertens Res 1995; 18: 99–110.
Julius S, Krause L, Schork NJ, et al: Hyperkinetic borderline hypertension in Tecumseh, Michigan. Hypertension 1991; 9: 77–84.
Grassi G, Mancia G : The function of the autonomic nervous system in hypertension, in Bolis L, Licinio J, Govoni S ( eds): Handbook of the Autonomic Nervous System. New York, Marcel Dekker, 2003, pp 425–438.
Grassi G, Vailati S, Bertinieri G, et al: Heart rate as marker of sympathetic activity. J Hypertens 1998; 16: 1635–1639.
Grassi G, Esler M : How to assess sympathetic activity in humans. J Hypertens 1999; 17: 719–734.
Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G : Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31: 68–72.
Grassi G, Seravalle G, Bertinieri G, et al: Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. J Hypertens 2000; 18: 587–593.
Greenwood JP, Scott EM, Stoker JB, Mary DA : Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol 2001; 38: 1711–1717.
Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD : Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108: 560–565.
Esler M, Ferrier C, Lambert G, Eisenhofer G, Cox H, Jennings G : Biochemical evidence of sympathetic hyperactivity in human hypertension. Hypertension 1991; 17: S29–S35.
Ferrier C, Esler MD, Eisenhofer G, et al: Increased norepinephrine spillover into the jugular veins in essential hypertension. Hypertension 1992; 19: 62–69.
Young JB, Macdonald IA : Sympathoadrenal activity in human obesity: heterogeneity of findings since 1980. Int J Obes Relat Metab Disord 1992; 16: 959–967.
Troisi RJ, Weiss ST, Parker DR, Sparrow D, Young JB, Landsberg L : Relation of obesity and diet to sympathetic nervous system activity. Hypertension 1991; 17: 669–677.
Grassi G, Seravalle G, Cattaneo BM, et al: Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25: 560–563.
Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M : Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 1997; 96: 3423–3429.
Grassi G, Dell'Oro R, Facchini A, Quarti Trevano F, Bolla GB, Mancia G : Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004; 22: 2363–2369.
Alvarez GE, Ballard TP, Beske SD, Davy KP : Subcutaneous obesity is not associated with sympathetic neural activation. Am J Physiol 2004; 287: H414–H418.
Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK : Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998; 98: 772–776.
Grassi G, Facchini A, Trevano FQ, et al: Obstructive sleep apnea–dependent and −independent adrenergic activation in obesity. Hypertension 2005; 46: 321–325.
Grassi G, Seravalle G, Dell'Oro R, Turri C, Bolla GB, Mancia G : Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000; 36: 538–542.
Brunner EJ, Hemingway H, Walker BR, et al: Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 2002; 106: 2659–2665.
Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ : Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab 2005; 90: 5998–6005.
Huggett RJ, Burns J, Mackintosh AF, Mary DA : Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 2004; 44: 847–852.
Grassi G, Dell'Oro R, Quarti-Trevano F, et al: Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005; 48: 1359–1365.
Arenare F, Quarti Trevano F, Dell'Oro R, et al: Metabolic syndrome potentiates the sympathetic and baroreflex dysfunction of heart failure state. J Hypertens 2006; 24: S6 ( Abstract).
Grassi G, Giannattasio C, Cleroux J, et al: Cardiopulmonary reflex before and after regression of left ventricular hypertrophy in essential hypertension. Hypertension 1988; 12: 227–237.
Narkiewicz K, van de Borne PJ, Pesek CA, Dyken ME, Montano N, Somers VK : Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation 1999; 99: 1183–1189.
Landsberg L : Obesity and the insulin resistance syndrome. Hypertens Res 1996; 19: S51–S55.
Egan BM : Insulin resistance and the sympathetic nervous system. Curr Hypertens Rep 2003; 5: 247–254.
Anderson EA, Balon TW, Hoffman RP, Sinkey CA, Mark AL : Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension 1992; 19: 621–627.
Scherrer U, Sartori C : Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997; 96: 4104–4113.
Grassi G, Seravalle G, Quarti Trevano F, et al: Potentiating effects of the metabolic syndrome on the sympathetic abnormalities characterizing human obesity. J Hypertens 2005; 23: S266 ( Abstract).
Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO : Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993; 21: 618–623.
Li YF, Wang W, Mayhan WG, Patel KP : Angiotensin-mediated increase in renal sympathetic nerve discharge within the PVN: role of nitric oxide. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1035–R1043.
Taddei S, Grassi G : Angiotensin II as the link between nitric oxide and neuroadrenergic function. J Hypertens 2005; 23: 935–937.
Grassi G : Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. J Hypertens 2001; 19: 1713–1716.
Grassi G, Seravalle G, Dell'Oro R, et al: CROSS Study. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21: 1761–1769.
Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ : Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14: 425–430.
Grassi G, Cattaneo BM, Seravalle G, et al: Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997; 96: 1173–1179.
Grassi G : Leptin, sympathetic nervous system, and baroreflex function. Curr Hypertens Rep 2004; 6: 236–240.
Rahmouni K, Correia ML, Haynes WG, Mark AL : Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45: 9–14.
Cohn JN, Levine TB, Olivari MT, et al: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819–823.
Rouleau JL, Packer M, Moye L, et al: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24: 583–591.
Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM : Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J 2001; 22: 1136–1143.
Gerson MC, McGuire N, Wagoner LE : Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. J Card Fail 2003; 9: 384–391.
Bristow MR, Krause-Steinrauf H, Nuzzo R, et al: Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation 2004; 110: 1437–1442.
Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B : Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J 2005; 26: 906–913.
Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B : Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology 2001; 57: 833–838.
Copie X, Hnatkova K, Staunton A, Fei L, Camm AJ, Malik M : Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two-year follow-up study. J Am Coll Cardiol 1996; 27: 270–276.
La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ, ATRAMI (Autonomic Tone and Reflexes after Myocardial Infarction) Investigators : Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998; 351: 478–484.
Benedict CR, Shelton B, Johnstone DE, SOLVD Investigators : Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996; 94: 690–697.
Endo A, Kinugawa T, Ogino K, et al: Cardiac and plasma catecholamine responses to exercise in patients with type 2 diabetes: prognostic implications for cardiac-cerebrovascular events. Am J Med Sci 2000; 320: 24–30.
Zoccali C, Mallamaci F, Parlongo S, et al: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354–1359.
Mancia G, Sega R, Cesana GC, et al: Metabolic syndrome in PAMELA population: prevalence, prognostic value, out-of-office blood pressures and cardiac damage. J Hypertens 2005; 23: S134 ( Abstract).
Sen S, Tarazi RC, Khairallah PA, Bumpus FM : Cardiac hypertrophy in spontaneously hypertensive rats. Circ Res 1974; 35: 775–781.
Patel MB, Stewart JM, Loud AV, et al: Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine. Circulation 1991; 84: 2091–2100.
Kelm M, Schafer S, Mingers S, et al: Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 1996; 14: 1357–1364.
Zoccali C, Mallamaci F, Tripepi G, et al: Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40: 41–46.
Seo HS, Kang TS, Park S, et al: Insulin resistance is associated with arterial stiffness in nondiabetic hypertensives independent of metabolic status. Hypertens Res 2005; 28: 945–951.
Grassi G, Giannattasio C, Failla M, et al: Sympathetic modulation of radial artery compliance in congestive heart failure. Hypertension 1995; 26: 348–354.
Grassi G, Giannattasio C : Obesity and vascular stiffness: when body fat has an adverse impact on arterial dynamics. J Hypertens 2005; 23: 1789–1791.
De Backer G, Ambrosioni E, Borch-Johnsen K, et al: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601–1610.
European Society of Hypertension–European Society of Cardiology Guidelines Committee : 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.
Grundy SM, Cleeman JI, Daniels SR, et al: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–2752.
Takeuchi H, Saitoh S, Takagi S, et al: Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program–Adult Treatment Panel III to Japanese men—the Tanno and Sobetsu Study. Hypertens Res 2005; 28: 203–208.
Palatini P, Benetos A, Grassi G, et al: Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24: 603–610.
Grassi G, Seravalle G, Colombo M, et al: Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998; 97: 2037–2042.
Grassi G, Seravalle G, Calhoun DA, Mancia G : Physical training and baroreceptor control of sympathetic nerve activity in humans. Hypertension 1994; 23: 294–301.
Iwane M, Arita M, Tomimoto S, et al: Walking 10,000 steps/day or more reduces blood pressure and sympathetic nerve activity in mild essential hypertension. Hypertens Res 2000; 23: 573–580.
Grassi G : Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens 2004; 13: 513–519.
Grassi G : Neuroadrenergic effects of calcium channel blockers: a developing concept. J Hypertens 2004; 22: 887–888.
van Zwieten PA : Centrally acting imidazoline I1−receptor agonists: do they have a place in the management of hypertension? Am J Cardiovasc Drugs 2001; 1: 321–326.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grassi, G. Sympathetic Overdrive and Cardiovascular Risk in the Metabolic Syndrome. Hypertens Res 29, 839–847 (2006). https://doi.org/10.1291/hypres.29.839
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.29.839
Keywords
This article is cited by
-
Dietary salt intake predicts future development of metabolic syndrome in the general population
Hypertension Research (2023)
-
High blood pressure with elevated resting heart rate: a high risk “Sympathetic” clinical phenotype
Hypertension Research (2023)
-
Comparison of EQ-5D-3L and metabolic components between patients with hyperhidrosis and the general population: a propensity score matching analysis
Quality of Life Research (2021)
-
Cardiovascular Risk Factors and Heart Rate Variability: Impact of the Level of the Threshold-Based Artefact Correction Used to Process the Heart Rate Variability Signal
Journal of Medical Systems (2021)
-
Changes in hemodynamics associated with metabolic syndrome are more pronounced in women than in men
Scientific Reports (2019)